Alliance Enhances ICON's Scientific Expertise and Access to
Investigators
DUBLIN--(BUSINESS WIRE)--
ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of
outsourced development services to the pharmaceutical, biotechnology and
medical device industries, today announced a strategic alliance with
Boston Clinical Research Institute (BCRI), an Academic Research
Organisation based in Boston, Massachusetts. The alliance will combine
BCRI's respected leadership in clinical strategy, study planning and
academic relationships with ICON's experience in the execution of global
clinical trials.
BCRI provides scientific consultancy in study design using expert
practising clinicians and key opinion leaders from premier medical
institutions, and also maintains a network of global investigators in
all of the medical specialties and subspecialties. BCRI also provides
academic leadership for Steering Committees, Advisory Panel
Participation, Endpoint Committees, Core Laboratory Services, and Data
Safety and Monitoring Boards.
"We are extremely pleased to announce the partnership with ICON,"
commented Dr. Michael Gibson, Founder and Senior Consultant at BCRI. "We
believe that the future of clinical research is collaboration between
the ARO and the CRO. ICON clearly recognises the incremental benefits of
collaboration with the thought leaders in the medical community to
optimise study planning, execution, and credibility."
Commenting on the alliance, Peter Gray, CEO at ICON plc, said, "We are
delighted that Dr. Gibson and BCRI have aligned with ICON. The
relationship provides ICON and its clients access to a breadth of
expertise in the key opinion leader community and to investigators
worldwide, including national and international leaders. Anticipated
benefits include enhanced planning, design, site selection and enrolment
performance."
Jonathan Goldman MD FACC, Executive Vice President of Strategic
Development at ICON Clinical Research, commented, "The relationship
between BCRI and ICON further enhances our scientific expertise and
access to investigators. We look forward to building on these
relationships to enhance our feasibility services and to optimise the
investment of our clients as a result of accelerated enrolment."
Notes to Editors
About Dr. C. Michael Gibson, M.S.,M.D., F.A.C.C.
Dr. C. Michael Gibson MS, MD, FACC, is an Associate Professor of
Medicine at Harvard Medical School and is a consulting Professor at the
Duke School of Medicine. Gibson has led his own ARO for twenty years and
has functioned as the principal investigator of numerous Phase I-IV
clinical trials of up to 15,000 patients and as a senior investigator in
the TIMI Study Group
About ICON plc
ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The Company
specialises in the strategic development, management and analysis of
programs that support clinical development - from compound selection to
Phase I-IV clinical studies. ICON currently has almost 8,000 employees,
operating from 77 locations in 38 countries.
Further information is available at www.iconplc.com
ICON/ICLR-G
Weber Shandwick
Yasamin Omoomian
Yomoomian@webershandwick.com
+44
(0) 2070 670 594
Source: ICON plc
News Provided by Acquire Media
